Skip to content
TrialScanner

NCT03189914

RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer

Phase 1/Phase 2CompletedPCSALead

Registry record

Lead sponsor
Processa Pharmaceuticals
Conditions
Metastatic Pancreatic Cancer
Primary completion
Oct 1, 2019Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03189914 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03189914: RX-3117 in Combination With... | TrialScanner